<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39338165</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Insulin Resistance in Long COVID-19 Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm14090911</ELocationID><Abstract><AbstractText><b>Background:</b> The COVID-19 pandemic has caused severe health issues worldwide and contributed to huge financial losses. Key comorbidities linked to an increased risk of severe COVID-19 and higher mortality rates include cardio-metabolic disorders such as type 1 and type 2 diabetes mellitus (T1DM and T2DM), atherosclerotic cardiovascular disease, chronic kidney disease, hypertension, heart failure, and obesity. The persistence of symptoms even after the acute phase is over is termed long COVID-19 syndrome. This study aimed to evaluate the relationship between long COVID-19 syndrome and the development of insulin resistance in previously non-diabetic patients. <b>Methods:</b> A prospective observational study was performed on 143 non-diabetic patients who had tested positive for SARS-CoV-2 infection by a PCR test and were hospitalized in our hospital between January 2020 and December 2022. The clinical and para-clinical data at 0, 4, and 12 months of hospital admission for post-COVID-19 infection follow-up was collected and labeled as t0, t4, and t12. Blood glucose, insulin, and C-peptide levels were measured at the beginning and further at 2, 5, 10, and 30 min after the intravenous arginine stimulation test. Similarly, BMI was calculated, and hs-CRP and ESR levels were noted. The results obtained were statistically analyzed. <b>Results:</b> More than one-third (30.7%) of the included patients developed long COVID-19 syndrome. It was found that 75% of patients with long COVID-19 hospitalized in our clinic developed diabetes within a year of acute infection with COVID-19; therefore, it can be said that the presence of long COVID-19 is a major risk for an altered metabolic status, which can cause diabetes. When comparing the glycemia levels (106 mg/dL) with the BMI at t0, t4, and t12 time intervals, the p-values were found to be 0.214, 0.042, and 0.058, respectively. Almost 62% of the patients having BMI &gt; 30 kg/m<sup>2</sup> were found to have an increase in blood glucose levels at 1 year. Similarly, insulin resistance was noted during this interval. A negative correlation of 0.40 for hsCRP and 0.38 for ESR was noted when compared with acute infection with COVID-19. <b>Conclusions:</b> The association between long COVID-19 and insulin resistance highlights the varied and widespread impacts of SARS-CoV-2 infection. Addressing the complexities of long COVID-19 requires a holistic strategy that encompasses both respiratory and metabolic considerations, which is crucial for enhancing the well-being of those enduring this persistent condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Dana Emilia</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0001-6585-0004</Identifier><AffiliationInfo><Affiliation>Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andor</LastName><ForeName>Minodora</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Discipline of Medical Semiotics II, Department V-Internal Medicine-1, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buda</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-3194-2012</Identifier><AffiliationInfo><Affiliation>Department I, Faculty of Pharmacy, University Clinic of Clinical Pharmacy, Communication in Pharmacy, Pharmaceutical Care, "Victor Babe&#x15f;" University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundnani</LastName><ForeName>Nilima Rajpal</ForeName><Initials>NR</Initials><Identifier Source="ORCID">0000-0002-2824-7182</Identifier><AffiliationInfo><Affiliation>Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duda-Seiman</LastName><ForeName>Daniel Marius</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craciun</LastName><ForeName>Laura Maria</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neagu</LastName><ForeName>Marioara Nicula</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0001-6288-3695</Identifier><AffiliationInfo><Affiliation>Faculty of Bioengineering of Animal Resources, Discipline of Physiology University of Life Sciences "King Mihai I" from Timi&#x219;oara, University of Life Sciences "King Mihai I", 300645 Timi&#x219;oara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlogea</LastName><ForeName>Iulia-Stefania</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Faculty Medicine, "Victor Babe&#x15f;" University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragan</LastName><ForeName>Simona-Ruxanda</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-3892-0211</Identifier><AffiliationInfo><Affiliation>Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">diabetes mellitus type 2</Keyword><Keyword MajorTopicYN="N">glucose impairment</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39338165</ArticleId><ArticleId IdType="pmc">PMC11433386</ArticleId><ArticleId IdType="doi">10.3390/jpm14090911</ArticleId><ArticleId IdType="pii">jpm14090911</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C., Schwarz P.E.H., Ludwig B., Linkermann A., Zimmet P., Kulebyakin K., Tkachuk V.A., Markov A.G., Lehnert H., de Angelis M.H., et al. COVID-19 and metabolic disease: Mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9:786&#x2013;798. doi: 10.1016/S2213-8587(21)00244-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00244-8</ArticleId><ArticleId IdType="pmc">PMC8489878</ArticleId><ArticleId IdType="pubmed">34619105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Yang D., Yang C., Zheng L., Huang K. Response to Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020;43:1399&#x2013;1407. doi: 10.2337/dc20-0660. Erratum in Diabetes Care 2020, 43, e165&#x2013;e166.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0660</ArticleId><ArticleId IdType="pubmed">32409498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukosd E.I., Kundnani N.R., Moise H.E., Stelian M., Bodea O.M., Minodoara A. Quality of Life of Chronic Heart Failure Patients During and After COVID-19: Observational Study Using EuroQoL-Visual Analogue Scales. Med. Sci. Monit. 2024;30:e943301. doi: 10.12659/MSM.943301.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.943301</ArticleId><ArticleId IdType="pmc">PMC11020506</ArticleId><ArticleId IdType="pubmed">38605505</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosca C.I., Branea H.S., Sharma A., Nicoras V.A., Borza C., Lighezan D.F., Morariu S.I., Kundnani N.R. Rhythm Disturbances in Post-Acute COVID-19 Syndrome in Young Men without Pre-Existing Known Cardiovascular Disease&#x2014;A Case Series. Biomedicines. 2023;11:1146. doi: 10.3390/biomedicines11041146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11041146</ArticleId><ArticleId IdType="pmc">PMC10136152</ArticleId><ArticleId IdType="pubmed">37189764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff E.R., Madlock-Brown C., Baratta J.M., Bhatia A., Davis H., Girvin A., Hill E., Kelly E., Kostka K., Loomba J., et al. Coding long COVID: Characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21:58. doi: 10.1186/s12916-023-02737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02737-6</ArticleId><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon P., Abrams N.D., Avula L.R., Carrick D.M., Chander P., Divi R.L., Dwyer J.T., Gannot G., Gordiyenko N., Liu Q., et al. Unraveling Links between Chronic Inflammation and Long COVID: Workshop Report. J. Immunol. 2024;212:505&#x2013;512. doi: 10.4049/jimmunol.2300804.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2300804</ArticleId><ArticleId IdType="pubmed">38315950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadeh F.H., Wilson D.R., Agrawal D.K. Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies. Arch. Microbiol. Immunol. 2023;7:36&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310313</ArticleId><ArticleId IdType="pubmed">37388279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapna F., Deepa F., Sakshi F., Sonam F., Kiran F., Perkash R.S., Bendari A., Kumar A., Rizvi Y., Suraksha F., et al. Unveiling the Mysteries of Long COVID Syndrome: Exploring the Distinct Tissue and Organ Pathologies Linked to Prolonged COVID-19 Symptoms. Cureus. 2023;15:e44588. doi: 10.7759/cureus.44588.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.44588</ArticleId><ArticleId IdType="pmc">PMC10545886</ArticleId><ArticleId IdType="pubmed">37795061</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res. Clin. Pract. 2020;167:108382. doi: 10.1016/j.diabres.2020.108382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108382</ArticleId><ArticleId IdType="pmc">PMC7445123</ArticleId><ArticleId IdType="pubmed">32853686</ArticleId></ArticleIdList></Reference><Reference><Citation>Manique I., Abeg&#xe3;o Matias A., Bou&#xe7;a B., Rego T., Cortez L., Sabino T., Panarra A., Rizzo M., Silva-Nunes J. Does the Hyperglycemia Impact on COVID-19 Outcomes Depend upon the Presence of Diabetes?&#x2014;An Observational Study. Metabolites. 2022;12:1116. doi: 10.3390/metabo12111116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12111116</ArticleId><ArticleId IdType="pmc">PMC9693757</ArticleId><ArticleId IdType="pubmed">36422255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramchandani B.P., Azmath M.F., Bendaram S.R., Mirza F.S. A Sweet Paradox: Severe Insulin Resistance and Hyperglycemia in Asymptomatic COVID-19 Infection. Cureus. 2023;15:e40477. doi: 10.7759/cureus.40477.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.40477</ArticleId><ArticleId IdType="pmc">PMC10349667</ArticleId><ArticleId IdType="pubmed">37456416</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte C., Cipponeri E., Roden M. Diabetes Mellitus, Energy Metabolism, and COVID-19. Endocr. Rev. 2024;45:281&#x2013;308. doi: 10.1210/endrev/bnad032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnad032</ArticleId><ArticleId IdType="pmc">PMC10911957</ArticleId><ArticleId IdType="pubmed">37934800</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Zhang S., Wang Z., Wang S., Ma Y., Ma P., Luo H., Wang M., Jin Y. Association Between Longitudinal Change in Abnormal Fasting Blood Glucose Levels and Outcome of COVID-19 Patients Without Previous Diagnosis of Diabetes. Front. Endocrinol. 2021;12:640529. doi: 10.3389/fendo.2021.640529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.640529</ArticleId><ArticleId IdType="pmc">PMC8042381</ArticleId><ArticleId IdType="pubmed">33859617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein S.R., Cozma D., Kamel M., Hamad M., Mohammad M.G., Khan N.A., Saber M.M., Semreen M.H., Steenblock C. Long-COVID, Metabolic and Endocrine Disease. Horm. Metab. Res. 2022;54:562&#x2013;566. doi: 10.1055/a-1878-9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1878-9307</ArticleId><ArticleId IdType="pmc">PMC9363148</ArticleId><ArticleId IdType="pubmed">35724687</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L., Ben Nasr M., D&#x2019;Addio F., Loretelli C., Rossi A., Pastore I., Daniele G., Abdelsalam A., Maestroni A., Dell&#x2019;Acqua M., et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 2021;3:774&#x2013;785. doi: 10.1038/s42255-021-00407-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00407-6</ArticleId><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel V., Raizada A., Aggarwal A., Madhu S.V., Kar R., Agrawal A., Mahla V., Goel A. Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study. Am. J. Trop. Med. Hyg. 2024;110:512&#x2013;517. doi: 10.4269/ajtmh.22-0695.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.22-0695</ArticleId><ArticleId IdType="pmc">PMC10919180</ArticleId><ArticleId IdType="pubmed">38350147</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Wang L., Zhou F., Li J., Liu Y., Yang S. Long-term effects of obesity on COVID-19 patients discharged from hospital. Immun. Inflamm. Dis. 2021;9:1678&#x2013;1685. doi: 10.1002/iid3.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.522</ArticleId><ArticleId IdType="pmc">PMC8589408</ArticleId><ArticleId IdType="pubmed">34499804</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohner M., Schwarz P.E.H., Bornstein S.R. Treating Insulin Resistance with Intermittent Personalized Nutrition to Sustain Metabolic Health and Functioning Immune System for Risk Reduction of Viral Diseases Especially COVID-19 and Long-COVID. Horm. Metab. Res. 2022;54:567&#x2013;570. doi: 10.1055/a-1864-8234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1864-8234</ArticleId><ArticleId IdType="pubmed">35636457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasmi A., Noor S., Menzel A., Do&#x15f;a A., Pivina L., Bj&#xf8;rklund G. Obesity and Insulin Resistance: Associations with Chronic Inflammation, Genetic and Epigenetic Factors. Curr. Med. Chem. 2021;28:800&#x2013;826. doi: 10.2174/0929867327666200824112056.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867327666200824112056</ArticleId><ArticleId IdType="pubmed">32838708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhau P.T., Gamede M., Sibiya N. COVID-19-Induced Diabetes Mellitus: Comprehensive Cellular and Molecular Mechanistic Insights. Pathophysiology. 2024;31:197&#x2013;209. doi: 10.3390/pathophysiology31020016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology31020016</ArticleId><ArticleId IdType="pmc">PMC11036300</ArticleId><ArticleId IdType="pubmed">38651404</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O&#x2019;Donnell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., An X., Yang C., Sun W., Ji H., Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 2023;14:1149239. doi: 10.3389/fendo.2023.1149239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1149239</ArticleId><ArticleId IdType="pmc">PMC10086443</ArticleId><ArticleId IdType="pubmed">37056675</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppelli A., Giannarelli R., Aragona M., Penno G., Falcone M., Tiseo G., Ghiadoni L., Barbieri G., Monzani F., Virdis A., et al. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020;43:2345&#x2013;2348. doi: 10.2337/dc20-1380.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1380</ArticleId><ArticleId IdType="pubmed">32788285</ArticleId></ArticleIdList></Reference><Reference><Citation>Potere N., Valeriani E., Candeloro M., Tana M., Porreca E., Abbate A., Spoto S., Rutjes A.W.S., Di Nisio M. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Crit. Care. 2020;24:389. doi: 10.1186/s13054-020-03022-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03022-1</ArticleId><ArticleId IdType="pmc">PMC7330272</ArticleId><ArticleId IdType="pubmed">32616077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Bae J.H., Kwon H.S., Nauck M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021;17:11&#x2013;30. doi: 10.1038/s41574-020-00435-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00435-4</ArticleId><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidu S., Gillies C., Zaccardi F., Kunutsor S.K., Hartmann-Boyce J., Yates T., Singh A.K., Davies M.J., Khunti K. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. Endocrinol. Diabetes Metab. 2021;4:e00176. doi: 10.1002/edm2.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/edm2.176</ArticleId><ArticleId IdType="pmc">PMC7460942</ArticleId><ArticleId IdType="pubmed">32904932</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo C., Visco V., Gambardella J., Ferruzzi G.J., Rispoli A., Rusciano M.R., Toni A.L., Virtuoso N., Carrizzo A., Di Pietro P., et al. Cardiovascular Implications of microRNAs in Coronavirus Disease 2019. J. Pharmacol. Exp. Ther. 2023;384:102&#x2013;108. doi: 10.1124/jpet.122.001210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.122.001210</ArticleId><ArticleId IdType="pubmed">35779946</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K., Kosiborod M., Ray K.K. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes. Metab. 2018;20:1337&#x2013;1341. doi: 10.1111/dom.13243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13243</ArticleId><ArticleId IdType="pubmed">29405543</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti A., Schuelter-Trevisol F., Iser B.P.M., Traebert E., Freiberger V., Ventura L., Rezin G.T., da Silva B.B., Meneghetti Dallacosta F., Grigollo L., et al. Obesity in people with diabetes in COVID-19 times: Important considerations and precautions to be taken. World J. Clin. Cases. 2021;9:5358&#x2013;5371. doi: 10.12998/wjcc.v9.i20.5358.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i20.5358</ArticleId><ArticleId IdType="pmc">PMC8281433</ArticleId><ArticleId IdType="pubmed">34307590</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Gillies C.L., Singh R., Singh A., Chudasama Y., Coles B., Seidu S., Zaccardi F., Davies M.J., Khunti K. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes. Metab. 2020;22:1915&#x2013;1924. doi: 10.1111/dom.14124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14124</ArticleId><ArticleId IdType="pmc">PMC7361304</ArticleId><ArticleId IdType="pubmed">32573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139:2022&#x2013;2031. doi: 10.1161/CIRCULATIONAHA.118.038868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.038868</ArticleId><ArticleId IdType="pubmed">30786725</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K. SGLT2 inhibitors in people with and without T2DM. Nat. Rev. Endocrinol. 2021;17:75&#x2013;76. doi: 10.1038/s41574-020-00453-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00453-2</ArticleId><ArticleId IdType="pubmed">33293703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>